58例成人急性非淋巴细胞白血病诱导化疗

A Comparison of MA and DA Regimen in Treatment of Acute Nonlymphoblastic Leukemia in 58 Adult Cases

本文报告MA和DA方案治疗急性非淋巴细胞白血病 (ANLL) 5 8例 ,其中 2 8例用MA方案 ,CR16例 (5 7 1% ) ;30例用DA方案 ,CR18例 (6 0 % ) ,两种方案CR率相似 (P >0 0 5 )。MA和DA方案治疗的MBDI分别为 39 4%、44 %(P >0 5 ) ,病人的中位缓解时间为 10 5月和 10月 ;2年持续CR率为 46 %和 44 %。MA方案的心脏毒性较DA的小 ,但骨髓抑制作用较DA略大。MA方案对白血病细胞的杀伤及效果表明 ,MA可做ANLL的一线治疗方案 ,具有实用价值。

From October 1995 to August 1988,58 untreated patients with acute nonlymphoblastic leukemia(ANLL) ranging in age from 14 to 65 years were randomized to receive MA( Mitoxantrone 10mg/day iv for 3 days, cytosine arabinoside 150mg/day iv for 7 days or DA(daunorubicin 40 mg/m\+2/day iv for 3days , cytosine arabinoside 150 mg/day iv for 7 days), 16 of 28 caces (57.1%) treated initially with MA and 18 of 30 cases(60%) treated initially with DA achieved complete remisson. Up to May 1999 the average remisson duration was 10.5 months in 12 patients treated with MA and 10 months in 12 patients treated with DA(P>0.05).The 2 year survival rate was 46% in MA and 44% in DA regimen.\;It was concluded that CR rate and survival rate MA and DA regimens were similar ,with side effects of cardiotoxity more serious in DA than in MA regimen and bone marrow depression more serious in MA than in DA regimen. The author therefore strongly recommended the MA regimen.